Stemline Therapeutics (Stemline Therapeutics) Price-to-Free-Cash-Flow : N/A (As of May. 05, 2024)

Stemline Therapeutics Price-to-Free-Cash-Flow Chart

Stemline Therapeutics Annual Data
	Trend	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19
Price-to-Free-Cash-Flow		Get a 7-Day Free Trial					-	-	-	-	-

Stemline Therapeutics Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Price-to-Free-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Stemline Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Stemline Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stemline Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stemline Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Stemline Therapeutics's Price-to-Free-Cash-Flow falls into.

Stemline Therapeutics Price-to-Free-Cash-Flow Calculation

Stemline Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Stemline Therapeutics's Share Price of today is $11.83.
Stemline Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.36.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Stemline Therapeutics  (NAS:STML) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.

Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.

Stemline Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Stemline Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Stemline Therapeutics (Stemline Therapeutics) Business Description